Hester Biosciences' Q1 FY 2025-26 Quarterly Results

Result Summary

• Hester Biosciences Ltd reported a 3.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 3.5%.
• Its expenses for the quarter were down by 9.1% QoQ and 8.8% YoY.
• The net profit increased 170.6% QoQ and increased 130.8% YoY.
• The earnings per share (EPS) of Hester Biosciences Ltd stood at 20.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Hester Biosciences Ltd is a prominent player in the biotechnology and pharmaceuticals sector, primarily engaged in the production and distribution of animal healthcare products. The company is recognized for its significant presence in the production of vaccines and health products for poultry and other animals. As a leader in the veterinary biological sector, Hester Biosciences has been actively expanding its product portfolio and market reach. However, specific recent major developments about the company are not available in the current dataset.

Revenue

In the first quarter of fiscal year 2026, Hester Biosciences Ltd reported a total income of ₹86.42 crores, reflecting a quarter-over-quarter (QoQ) increase of 3.6% from ₹83.40 crores in Q4FY25. The year-over-year (YoY) growth from Q1FY25, where the revenue stood at ₹83.49 crores, is marked by an increase of 3.5%. These metrics indicate a consistent upward trajectory in revenue generation for Hester Biosciences over the analyzed periods.

Profitability

The profitability metrics for Hester Biosciences Ltd indicate robust growth. The profit before tax (PBT) for Q1FY26 was ₹19.14 crores, representing a significant QoQ surge of 103.8% from ₹9.39 crores in Q4FY25. When compared to Q1FY25's PBT of ₹9.73 crores, this marks a YoY increase of 96.7%. The profit after tax (PAT) similarly exhibited strong performance, reaching ₹17.29 crores in Q1FY26, which is a 170.6% QoQ growth from ₹6.39 crores in Q4FY25 and a 130.8% YoY growth from ₹7.49 crores in Q1FY25. Earnings per share (EPS) for Q1FY26 also increased significantly, recorded at ₹20.30, compared to ₹7.50 in Q4FY25 and ₹8.80 in Q1FY25, showing both QoQ and YoY growth of over 170%.

Operating Metrics

The total expenses for Hester Biosciences in Q1FY26 were ₹67.28 crores, showing a decrease of 9.1% QoQ from ₹74.01 crores in Q4FY25 and a YoY decrease of 8.8% from ₹73.76 crores in Q1FY25. This reduction in expenses, paired with the increase in revenue, contributed to the enhanced profitability metrics. The tax expense for Q1FY26 was ₹2.89 crores, which decreased by 16.7% QoQ from ₹3.47 crores in Q4FY25 and by 7.1% YoY from ₹3.11 crores in Q1FY25. These figures indicate effective cost management strategies implemented by the company during the period.